Correlation of flow cytometry to clinical factors, hormone receptors, and histopathological grade in stage I and II invasive breast carcinoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 19, Issue 1, 1996, Pages 54-58

  Haghbin, Mahroo ^a   McCue, Peter A ^a   Mansfield, Carl M ^b   Komarnicky, Lydia T ^b   Benammar, Alia ^b   Schwartz, Gordon F ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^b NONE

Author keywords

Breast cancer; Flow cytometry; Prognostic factors

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CORRELATION FUNCTION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; TUMOR VOLUME;

BREAST NEOPLASMS; DNA, NEOPLASM; FEMALE; FLOW CYTOMETRY; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PLOIDIES; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; S PHASE;

EID: 0030060289     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199602000-00012     Document Type: Article

References (45)

1. Dressler LG, Seamer LC, Owens MA, Clark GM, McGuire WL. DNA flow cytometry and prognostic factors in 1,331 frozen breast cancer specimens. Cancer 1988;61:420-7.
2. Frierson HF Jr. Ploidy analyses and S-phase fraction determination by flow cytometry of invasive adenocarcinomas of the breast. Am J Surg Pathol 1991;15:358-67.
3. Ewers SB, Langstrom E, Baldetorp B, Killander D. Flow-cytometric DNA analysis in primary breast carcinomas and clinicopathological correlations. Cytometry 1984;5:408-19.
4. Hedley DW, Rugg CA, Gelber RD. Association of DNA index and S-phase fraction with prognosis of nodes positive early breast cancer. Cancer Res 1987;47:4729-35.
5. Berryman IL, Harvey JM, Sterrett GF, Papadimitriou JM. The nuclear DNA content of human breast carcinoma. Associations with clinical stage, axillary lymph node status, estrogen receptor status and outcome. Anal Quant Cytol Histol 1987;9:429-34.
6. Cornelisse CJ, Van de Velde CJH, Caspers RJC, Moolenaar AJ, Hermans J. DNA ploidy and survival in breast cancer patients. Cytometry 1987;8:225-34.
7. Kallioniemi OP, Hietanen T, Mattila J, Lehtinen M. Lauslahti K, Koivula T. Aneuploid DNA content and high S-phase fraction of tumour cells are related to poor prognosis in patients with primary breast cancer. Eur J Cancer Clin Oncol 1987;23:277-82.
8. Fallenius AG, Auer GU, Carstensen JM. Prognostic significance of DNA measurements in 409 consecutive breast cancer patients. Cancer 1988;62:331-41.
9. Eskelinen MJ, Pajarinen P, Collan Y, et al. Relationship between DNA ploidy and survival in patients with primary breast cancer. Br J Surg 1989;76:830-4.
10. Clark GM, Dressier LG, Owens MA, Pounds G, Oldaker T, McGuire WL. Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 1989;320:627-33.
11. Kute TE, Muss HB, Cooper MR, et al. The use of flow cytometry for prognosis of stage II adjuvant treated breast cancer patients. Cancer 1990;66:1810-16.
12. O'Reilly SM, Camplejohn RS, Barnes DM, et al. DNA index, S-phase fraction, histological grade and prognosis in breast cancer. Br J Cancer 1990;61:671-4.
13. Joensuu H, Toikkanen S, Klemi PJ. DNA index and S-phase fraction and their combination as prognostic factors in operable ductal breast carcinoma. Cancer 1990;66:331-40.
14. Visscher DW, Zarbo RJ, Jacobson G, et al. Multiparametric deoxyribonucleic acid and cell cycle analysis of breast carcinomas by flow cytometry. Lab Invest 1990;62:370-8.
15. McGuire WL, Tandon AK, Allred DC, Chamness GC, Clark GM. How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst 1990;82:1006-14.
16. Clark GM, Wenger CR, Beardslee S, et al. How to integrate steroid hormone receptor, flow cytometric, and other prognostic information in regard to primary breast cancer. Cancer 1993;71: 2157-62.
17. Stal O, Dufmats M, Hatschek T, et al. S-phase fraction is a prognostic factor in stage I breast carcinoma. J Clin Oncol 1993;11: 1717-22.
18. Fisher B, Gunduz N, Costantino J, et al. DNA flow cytometric analysis of primary operable breast cancer. Cancer 1991;68:1465-75.
19. Merkel DE, Winchester DJ, Goldschmidt RA, August CZ, Wruck DM, Rademaker AW. DNA flow cytometry and pathologic grading as prognostic guides in axillary lymph node-negative breast cancer. Cancer 1993;72:1926-32.
20. Moran RE, Black MM, Alpert L, Straus MJ. Correlation of cell-cycle kinetics, hormone receptors, histopathology, and nodal status in human breast cancer. Cancer 1984;45:1586-90.
21. Horsfall DJ, Tilley WD, Orell SR, Marshall VR, McK. Cant EL. Relationship between ploidy and steroid hormone receptors in primary invasive breast cancer. Br J Cancer 1986;53:23-8.
22. Feichter GE, Mueller A, Kaufmann M, et al. Correlation of DNA flow cytometric results and other prognostic factors in primary breast cancer. Int J Cancer 1988;41:823-8.
23. Muss HB, Kute TE, Case LD, et al. The relation of flow cytometry to clinical and biologic characteristics in women with node negative primary breast cancer. Cancer 1989;64:1894-1900.
24. Shintaku IP, Said JW. Detection of estrogen receptors with monoclonal antibodies in routinely processed formalin-fixed paraffin sections of breast carcinoma. Am J Clin Pathol 1987;87: 161-7.
25. Vindelov L, Christenson IJ, Nissen NI. A detergent-trypsin method of the preparation of nuclei for flow cytometric DNA analysis. Cytometry 1983;3:323-7.
26. Siegel S. Non-parametric statistics for behavioral sciences. New York: McGraw-Hill, 1956.
27. Russo J, Frederick J, Ownby HE, et al. Predictors of recurrence and survival of patients with breast cancer. Am J Clin Pathol 1987;88:123-31.
28. Meyer JS, Friedman E, McCrate MM, Bauer WC. Prediction of early course of breast carcinoma by thymidine labeling. Cancer 1983;51:1879-86.
29. Tubiana M, Pejovic MH, Chavaudra N, Contesso G, Malaise EP. The long-term prognostic significance of the thymidine labeling index in breast cancer. Int J Cancer 1984;33:441-5.
30. Silvestini R, Daidone MG, DiFronzo G, Morabito A, Valagussa P, Bonodonna G. Prognostic implication of labeling index versus estrogen receptors and tumor size in node-negative breast cancer. Breast Cancer Res Treat 1986;7:161-9.
31. Courdi A, Hery M, Dahan E, et al. Factors affecting relapse in node-negative breast cancer. A multivariate analysis including the labeling index. Eur J Cancer Clin Oncol 1989;25:351-6.
32. Hedley DW, Clark GM, Cornelisse CJ, Killander D, Kute T, Merkel D. Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast. Cytometry 1993;14:482-5.
33. Batsakis JG, Sneige N, El Naggar AK. Flow cytometric (DNA content and S-phase fraction) analysis of breast cancer. Cancer 1993;71:2151-3.
34. Dressier LG, Gray R, Tormey DC, et al. Prediction of recurrence and therapy response in the node negative breast cancer patient by DNA flow cytometry: an Eastern Cooperative Oncology Group (ECOG) intergroup study (EST 7186; SWOG 8696; INT 0076) Breast Cancer Res Treat 1989;14:133.
35. Remvikos Y, Beuzeboc P, Zajdela A, Voillemot N, Magdelenat H, Pouillart P. Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy. J Nail Cancer Inst 1989;81:1383-7.
36. 1M0) breast carcinoma. J Clin Oncol 1989;7:355-66.
37. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer. Br J Cancer 1957;11:359-77.
38. Scarff RW, Toroni H. Histological typing of breast tumors. Geneva: WHO, 1968:510-13.
39. Fisher ER, Redmond C, Fisher B. Histologic grading of breast cancer. Pathol Annu 1980;15:239-51.
40. Le Doussal V, Tubiana-Hulin M, Friedman S, Hacene K, Spyratos F, Brunet M. Prognostic value of histologic grade nuclear components of Scraff-Bloom-Richardson. An improved score modification based on a multivariate analysis of 1,262 invasive ductal breast carcinomas. Cancer 1989;64:1914-21.
41. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-10.
42. Fisher B, Redmond C, Fisher ER, Caplan R. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol 1988;6:1076-87.
43. Walker RA, Camplejohn RS. Comparison of monoclonal antibody Ki-67 reactivity with grade and DNA flow cytometry of breast carcinomas. Br J Cancer 1988;57:281-3.
44. Isola JJ, Helin HJ, Helle MJ, Kallioniemi OP. Evaluation of cell proliferation in breast carcinoma. Comparison of Ki-67 immunohistochemical study. DNA flow cytometric analysis and mitotic count. Cancer 1990;65:1180-4.
45. Wintzer HO, Zipfel I, Schulte-Monting J, Hellerich U, Von Kleist S. Ki-67 immunostaining in human breast tumors and its relationship to prognosis. Cancer 1991;67:421-8.